Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Dec 1;21(12):1090-1101.
doi: 10.1093/ijnp/pyy082.

Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone

Marcos Gómez-Revuelta  1   2 , José María Pelayo-Terán  1   2   3 , María Juncal-Ruiz  1   2 , Víctor Ortiz-García de la Foz  1   2 , Javier Vázquez-Bourgon  1   2 , Ana González-Pinto  2   4 , Benedicto Crespo-Facorro  1   2
Affiliations
Randomized Controlled Trial

Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone

Marcos Gómez-Revuelta et al. Int J Neuropsychopharmacol. .

Abstract

Background: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up.

Method: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy.

Results: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (χ2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ2=9.617; P=.008) and increased sleep duration (χ2=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines.

Conclusions: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.

Trial registration: ClinicalTrials.gov NCT02526030.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consort flow diagram of subject through the phases of the randomized trial.
Figure 2.
Figure 2.
Kaplan-Meyer survival graph: All-cause discontinuation.
See this image and copyright information in PMC

References

    1. Addington D, Addington J, Maticka-Tyndale E(1993)Assessing depression in schizophrenia: the Calgary depression scale. Br J Psychiatry 22:39–44. - PubMed
    1. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, McGorry PD, Gleeson JF(2012)Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139:116–128 - PubMed
    1. Andreasen N.(1984)The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
    1. Andreasen NC.(1989)Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry 155:53–58. - PubMed
    1. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S(2013)Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006625.pub3. - PMC - PubMed

Publication types

MeSH terms

Associated data